Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report report published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Aptevo Therapeutics stock opened at $0.31 on Friday. The stock’s 50 day moving average is $0.22 and its 200 day moving average is $0.42. Aptevo Therapeutics has a twelve month low of $0.14 and a twelve month high of $10.80.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.